Skip to main content
Erschienen in: AIDS and Behavior 3/2017

13.09.2016 | Original Article

Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States

verfasst von: Rose Zulliger, Cathy Maulsby, Liza Solomon, Chanza Baytop, Alex Orr, Muazzam Nasrullah, Luke Shouse, Elizabeth DiNenno, David Holtgrave

Erschienen in: AIDS and Behavior | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Few groups in the United States (US) are as heavily affected by HIV as men who have sex with men (MSM), yet many MSM remain unaware of their infection. HIV diagnosis is important for decreasing onward transmission and promoting effective treatment for HIV, but the cost-effectiveness of testing programs is not well-established. This study reports on the costs and cost-utility of the MSM Testing Initiative (MTI) to newly diagnose HIV among MSM and link them to medical care. Cost and testing data in 15 US cities from January 2013 to March 2014 were prospectively collected and combined to determine the cost-utility of MTI in each city in terms of the cost per Quality Adjusted Life Years (QALY) saved from payer and societal perspectives. The total venue-based HIV testing costs ranged from $18,759 to $564,284 for nine to fifteen months of MTI implementation. The cost-saving threshold for HIV testing of MSM was $20,645 per new HIV diagnosis. Overall, 27,475 men were tested through venue-based MTI, of whom 807 (3 %) were newly diagnosed with HIV. These new diagnoses were associated with approximately 47 averted HIV infections. The cost per QALY saved by implementation of MTI in each city was negative, indicating that MTI venue-based testing was cost-saving in all cities. The cost-utility of social network and couples testing strategies was, however, dependent on whether the programs newly diagnosed MSM. The cost per new HIV diagnosis varied considerably across cities and was influenced by both the local cost of MSM testing implementation and by the seropositivity rate of those reached by the HIV testing program. While the cost-saving threshold for HIV testing is highly achievable, testing programs must successfully reach undiagnosed HIV-positive individuals in order to be cost-effective. This underscores the need for HIV testing programs which target and engage populations such as MSM who are most likely to have undiagnosed HIV to maximize programmatic benefit and cost-utility.
Literatur
1.
Zurück zum Zitat Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007–2010. HIV Surveill Suppl Rep. 2012;17(4):1–26. Centers for Disease Control and Prevention. Estimated HIV incidence in the United States, 2007–2010. HIV Surveill Suppl Rep. 2012;17(4):1–26.
2.
Zurück zum Zitat Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas. HIV Surveill Suppl Rep. 2014;19(3). Centers for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data—United States and 6 dependent areas. HIV Surveill Suppl Rep. 2014;19(3).
3.
Zurück zum Zitat Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. New Engl J Med. 2009;360(18):1815–26.CrossRefPubMedPubMedCentral Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. New Engl J Med. 2009;360(18):1815–26.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. New Engl J Med. 2011;365(6):493–505.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380–2.CrossRefPubMed Dieffenbach CW, Fauci AS. Universal voluntary testing and treatment for prevention of HIV transmission. JAMA. 2009;301(22):2380–2.CrossRefPubMed
6.
Zurück zum Zitat Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57.CrossRefPubMed
7.
Zurück zum Zitat Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2013;382(9899):1195–203.CrossRefPubMed Jia Z, Mao Y, Zhang F, Ruan Y, Ma Y, Li J, et al. Antiretroviral therapy to prevent HIV transmission in serodiscordant couples in China (2003-11): a national observational cohort study. Lancet. 2013;382(9899):1195–203.CrossRefPubMed
8.
Zurück zum Zitat Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas. HIV Surveill Rep. 2013;2013:25 Epub February 2015. Centers for Disease Control and Prevention. Diagnoses of HIV infection in the United States and dependent areas. HIV Surveill Rep. 2013;2013:25 Epub February 2015.
9.
Zurück zum Zitat Wejnert C, Le B, Rose CE, Oster AM, Smith AJ, Zhu J, et al. HIV infection and awareness among men who have sex with men-20 cities, United States, 2008 and 2011. PloS One. 2013;8(10):e76878.CrossRefPubMedPubMedCentral Wejnert C, Le B, Rose CE, Oster AM, Smith AJ, Zhu J, et al. HIV infection and awareness among men who have sex with men-20 cities, United States, 2008 and 2011. PloS One. 2013;8(10):e76878.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMed Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17.PubMed
11.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV Testing among men who have sex with men— 21 Cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):694–9. Centers for Disease Control and Prevention. HIV Testing among men who have sex with men— 21 Cities, United States, 2008. MMWR Morb Mortal Wkly Rep. 2011;60(21):694–9.
12.
Zurück zum Zitat MacKellar DA, Gallagher KM, Finlayson T, Sanchez T, Lansky A, Sullivan PS. Surveillance of HIV risk and prevention behaviors of men who have sex with men–a national application of venue-based, time-space sampling. Public health Rep. 2007;122(Suppl 1):39–47.CrossRefPubMedPubMedCentral MacKellar DA, Gallagher KM, Finlayson T, Sanchez T, Lansky A, Sullivan PS. Surveillance of HIV risk and prevention behaviors of men who have sex with men–a national application of venue-based, time-space sampling. Public health Rep. 2007;122(Suppl 1):39–47.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Kim JJ, Maulsby C, Zulliger R, Jain K, Positive Charge Intervention T, Charles V, et al. Cost and threshold analysis of positive charge, a multi-site linkage to HIV care program in the United States. AIDS Behav. 2015;19(10):1735–41.CrossRefPubMed Kim JJ, Maulsby C, Zulliger R, Jain K, Positive Charge Intervention T, Charles V, et al. Cost and threshold analysis of positive charge, a multi-site linkage to HIV care program in the United States. AIDS Behav. 2015;19(10):1735–41.CrossRefPubMed
16.
Zurück zum Zitat Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed Skarbinski J, Rosenberg E, Paz-Bailey G, Hall HI, Rose CE, Viall AH, et al. Human immunodeficiency virus transmission at each step of the care continuum in the United States. JAMA Intern Med. 2015;175(4):588–96.CrossRefPubMed
17.
Zurück zum Zitat Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632–6.CrossRefPubMed Hall HI, Holtgrave DR, Tang T, Rhodes P. HIV transmission in the United States: considerations of viral load, risk behavior, and health disparities. AIDS Behav. 2013;17(5):1632–6.CrossRefPubMed
18.
Zurück zum Zitat Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–9.CrossRefPubMed Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. J Acquir Immune Defic Syndr. 2013;64(2):183–9.CrossRefPubMed
19.
Zurück zum Zitat Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8.CrossRefPubMed Farnham PG, Holtgrave DR, Gopalappa C, Hutchinson AB, Sansom SL. Lifetime costs and quality-adjusted life years saved from HIV prevention in the test and treat era. J Acquir Immune Defic Syndr. 2013;64(2):e15–8.CrossRefPubMed
20.
Zurück zum Zitat CPI for All urban consumers (CPI-U) 1982–84 = 100 (Unadjusted)—CUUR0000SA0 [Internet]. 2014. CPI for All urban consumers (CPI-U) 1982–84 = 100 (Unadjusted)—CUUR0000SA0 [Internet]. 2014.
21.
Zurück zum Zitat Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. Jama. 1996;276(16):1339–41.CrossRefPubMed Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on cost-effectiveness in health and medicine. Jama. 1996;276(16):1339–41.CrossRefPubMed
22.
Zurück zum Zitat Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. Jama. 1996;276(15):1253–8.CrossRefPubMed Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. Jama. 1996;276(15):1253–8.CrossRefPubMed
23.
Zurück zum Zitat Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.CrossRefPubMedPubMedCentral Walensky RP, Freedberg KA, Weinstein MC, Paltiel AD. Cost-effectiveness of HIV testing and treatment in the United States. Clin Infect Dis. 2007;45(Suppl 4):S248–54.CrossRefPubMedPubMedCentral
Metadaten
Titel
Cost-utility of HIV Testing Programs Among Men Who Have Sex with Men in the United States
verfasst von
Rose Zulliger
Cathy Maulsby
Liza Solomon
Chanza Baytop
Alex Orr
Muazzam Nasrullah
Luke Shouse
Elizabeth DiNenno
David Holtgrave
Publikationsdatum
13.09.2016
Verlag
Springer US
Erschienen in
AIDS and Behavior / Ausgabe 3/2017
Print ISSN: 1090-7165
Elektronische ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1547-y

Weitere Artikel der Ausgabe 3/2017

AIDS and Behavior 3/2017 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.